NEURL1: A Potential Drug Target and Biomarker (G9148)

Target Name: NEURL1

NCBI ID: G9148

NEURL1

NEURL1: A Potential Drug Target and Biomarker

Neuralized-like protein 1 (NEURL1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a growing interest in the field of neuroscience.

NEURL1 is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, and muscle. Its primary function is to regulate the activity of a protein called GLUT4, which is involved in glucose metabolism. GLUT4 is a critical regulator of glucose uptake and storage in the body, and its dysfunction has been implicated in a number of diseases, including type 2 diabetes, obesity, and neurodegenerative disorders.

One of the key features of NEURL1 is its ability to interact with GLUT4. This interaction allows NEURL1 to regulate the activity of GLUT4 and influence its function. This interaction also makes it a potential target for drugs that are designed to modulate GLUT4 activity.

In cancer, GLUT4 has been shown to play a role in the development and progression of many types of cancer. For example, GLUT4 has been shown to be overexpressed in many types of cancer, including breast, lung, and ovarian cancer. Its overexpression has been linked to the development of cancer stem cells, which are cells that are capable of self-replication and have the potential to give rise to new, independent tumors.

In addition to its role in cancer, NEURL1 has also been shown to be involved in the development and progression of neurodegenerative disorders. For example, NEURL1 has been shown to be involved in the development of Alzheimer's disease, a type of neurodegenerative disorder that is characterized by the progressive loss of brain cells.

In addition to its potential role in disease, NEURL1 has also been shown to be a potential biomarker for a number of diseases. For example, its expression has been shown to be elevated in the brains of individuals with Alzheimer's disease, and its levels have been linked to the severity of the disease.

Given its unique structure and function, NEURL1 has the potential to be a valuable drug target and biomarker for a variety of diseases. Its ability to interact with GLUT4 and its expression in a variety of tissues make it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a growing interest in the field of neuroscience.

In conclusion, NEURL1 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and function make it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a growing interest in the field of neuroscience. Further research is needed to fully understand its role in disease and its potential as a drug or biomarker.

Protein Name: Neuralized E3 Ubiquitin Protein Ligase 1

Functions: Plays a role in hippocampal-dependent synaptic plasticity, learning and memory. Involved in the formation of spines and functional synaptic contacts by modulating the translational activity of the cytoplasmic polyadenylation element-binding protein CPEB3. Promotes ubiquitination of CPEB3, and hence induces CPEB3-dependent mRNA translation activation of glutamate receptor GRIA1 and GRIA2. Can function as an E3 ubiquitin-protein ligase to activate monoubiquitination of JAG1 (in vitro), thereby regulating the Notch pathway. Acts as a tumor suppressor; inhibits malignant cell transformation of medulloblastoma (MB) cells by inhibiting the Notch signaling pathway

The "NEURL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEURL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets